EyePoint Pharmaceuticals, Inc. (EYPT)

12,67 +1,11 (+9,60%) Alla chiusura: 04:00PM EDT

EyePoint Pharmaceuticals, Inc.

480 Pleasant Street
Suite A-210
Watertown, MA 02472
United States
617 926 5000
https://eyepointpharma.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 121

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Jay S. Duker M.D.	President, CEO & Director	1,29M	N/D	1959
Mr. George O. Elston	Executive VP & CFO	905,34k	N/D	1965
Dr. John B. Landis M.S., Ph.D.	Interim Head of R&D and Director	67,5k	N/D	1953
Mr. Michael J. Maciocio	Senior Vice President of Manufacturing & Operations	N/D	N/D	N/D
Mr. Ron I. Honig Esq.	Chief Legal Officer & Company Secretary	N/D	N/D	N/D
Ms. Jennifer Leonard	Chief People Officer & Senior VP of IT	N/D	N/D	N/D
Mr. David Scott Jones M.A.	Senior VP & Chief Commercial Officer	672,08k	N/D	1967
Mr. Michael Pine	Chief Business Officer	764,85k	N/D	1977
Ms. Isabelle Lefebvre	Chief Regulatory Officer	N/D	N/D	N/D
Dr. Marcia Sellos-Moura Ph.D.	Senior Vice President of Program Leadership	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di EyePoint Pharmaceuticals, Inc. al 1 maggio 2024 è 6. I criteri di valutazione fondamentali sono revisione: 10; Consiglio di Amministrazione: 3; diritti degli azionisti: 4; retribuzione: 7.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.